Multiple Endocrine Neoplasia — Written Clinical Reasoning · Phys Written Answers

Prompt

DCE-style written reasoning for Multiple Endocrine Neoplasia.

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Multiple Endocrine Neoplasia and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Thelen AE, Hogan EM, Su MW, McHenry CR The Genetics of Familial Neoplastic Thyroid Disease and Primary Hyperparathyroidism Surg Clin North Am, 2026.PMID 42419309
[2]Noso S, Miki H, Hiromine Y, Babaya N, et al. Metachronous multiple insulinomas in oculo-facio-cardio-dental syndrome harboring a novel BCOR deletion: a case report with review of literature Endocr J, 2026.PMID 42324136
[3]Nosé V, Canberk S, Baloch Z Recognizing Familial Thyroid Neoplasia: The Pathologist's Role in Diagnosis and Management Adv Anat Pathol, 2026.PMID 42319956
[4]Pawlak KM, Jagielski M, Papanikolaou IS, Hong W, et al. Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound Best Pract Res Clin Gastroenterol, 2026.PMID 42167859
[5]Mariën L, Chhajlani S, De Herdt C, Ceulemans K, et al. Germline MEN1 testing patterns in patients with neuroendocrine tumors: A 12-year retrospective analysis within NETwerk, an ENETS center of excellence J Neuroendocrinol, 2026.PMID 42140697
[6]Moura MJ, Chatterjee A, Wali S, Garza DR, et al. Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review Expert Opin Drug Saf, 2026.PMID 41995025
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Multiple Endocrine Neoplasia and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Thelen AE, Hogan EM, Su MW, McHenry CR The Genetics of Familial Neoplastic Thyroid Disease and Primary Hyperparathyroidism Surg Clin North Am, 2026.PMID 42419309
[2]Noso S, Miki H, Hiromine Y, Babaya N, et al. Metachronous multiple insulinomas in oculo-facio-cardio-dental syndrome harboring a novel BCOR deletion: a case report with review of literature Endocr J, 2026.PMID 42324136
[3]Nosé V, Canberk S, Baloch Z Recognizing Familial Thyroid Neoplasia: The Pathologist's Role in Diagnosis and Management Adv Anat Pathol, 2026.PMID 42319956
[4]Pawlak KM, Jagielski M, Papanikolaou IS, Hong W, et al. Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound Best Pract Res Clin Gastroenterol, 2026.PMID 42167859
[5]Mariën L, Chhajlani S, De Herdt C, Ceulemans K, et al. Germline MEN1 testing patterns in patients with neuroendocrine tumors: A 12-year retrospective analysis within NETwerk, an ENETS center of excellence J Neuroendocrinol, 2026.PMID 42140697
[6]Moura MJ, Chatterjee A, Wali S, Garza DR, et al. Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review Expert Opin Drug Saf, 2026.PMID 41995025
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922